QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 ubs-maintains-buy-on-johnson--johnson-raises-price-target-to-214

UBS analyst Danielle Antalffy maintains Johnson & Johnson (NYSE:JNJ) with a Buy and raises the price target from $190 to...

 johnson--johnson-cfo-joseph-wolk-says-2026-adj-eps-expected-to-exceed-current-street-estimates-by-as-much-as-5-cents

- Conf Call

 johnson--johnson-cfo-joseph-wolk-says-expect-rulings-on-certain-legal-motions-pending-in-talc-litigation-by-q1-2026-says-2026-revenue-growth-in-total-expected-to-exceed-5-above-current-street-estimates

- Conf Call

 johnson--johnson-to-separate-orthopedics-business-boosts-annual-sales-outlook

Johnson & Johnson beats Q3 estimates, raises 2025 sales guidance, and announces plans to spin off its $9.2 billion orthoped...

 stock-market-today-dow-jones-nasdaq-futures-tumble-ahead-of-big-bank-earningsgoldman-sachs-jpmorgan-citigroup-in-focus-updated

Editor’s Note: The future prices of benchmark tracking ETFs, the lede, and the latest economic releases were updated in the sto...

 johnson--johnson-intends-to-separate-its-orthopedics-business-and-establish-a-standalone-business-operating-as-depuy-synthes

Strengthens focus of Johnson & Johnson as an innovation powerhouse and accelerates the portfolio shift of its MedTech Segme...

 johnson--johnson-affirms-fy2025-adj-eps-guidance-of-1080-1090-vs-1087-est-raises-fy2025-sales-guidance-from-93200b-93600b-to-93500b-93900b-vs-93436b-est

($ in Billions, except EPS)October 2025July 2025Adjusted Operational Sales1,2,5Change vs. Prior Year / Mid-point3.5% – 4.0% / 3...

 goldman-sachs-jpmorgan-chase-and-3-stocks-to-watch-heading-into-tuesday

US stock futures lower, focus on Goldman Sachs, JPMorgan, Polaris, Johnson & Johnson, and Citigroup earnings.

 atai-life-sciences-remains-undervalued-analyst-initiates-with-around-125-stock-upside

Atai Life Sciences' BPL-003 shows strong Phase 2b results for treatment-resistant depression, with potential $2.5 billion s...

 johnson--johnson-q3-preview-with-stock-near-all-time-highs-heres-what-to-watch

Johnson & Johnson stock trades near all-time highs with an upcoming Q3 earnings report acting as the next catalyst.

 fda-adds-new-warning-for-johnson--johnsons-cancer-cell-therapy

FDA updates Johnson & Johnson's Carvykti label to warn of rare immune-related enterocolitis while reaffirming the thera...

 retail-investors-top-stocks-with-earnings-this-week-fastenal-asml-tsmc-and-more

Retail investors are preparing for the kick-off of the Q3 earnings season, with big banks and other top stocks reporting this w...

 fda-approves-labeling-changes-including-boxed-warning-for-immune-effector-cell-associated-enterocolitis-after-treatment-with-ciltacabtagene-autoleucel--determined-overall-benefit-of-carvykti-continues-to-outweigh-potential-risks-for-approved-use

https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/fda-approves-labeling-changes-include-boxed-warning-...

 johnson--johnson-warns-shareholders-to-reject-mini-tender-offer-by-tutanota-to-purchase-up-to-500k-shares-of-the-companys-common-stock-at-a-price-of-14500share-in-cash

Johnson & Johnson (NYSE:JNJ) today announced that it has received notice of an unsolicited mini-tender offer by Tutanota LL...

 morgan-stanley-maintains-equal-weight-on-johnson--johnson-raises-price-target-to-178

Morgan Stanley analyst Terence Flynn maintains Johnson & Johnson (NYSE:JNJ) with a Equal-Weight and raises the price tar...

 johnson--johnson-in-talks-to-acquire-protagonist-therapeutics-report

Johnson & Johnson is in talks to buy Protagonist Therapeutics in a deal that could expand its immunology and cancer drug po...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION